Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;41(8):2072-2087.
doi: 10.1038/s41372-021-01018-5. Epub 2021 Mar 23.

Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial

Collaborators, Affiliations
Randomized Controlled Trial

Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial

Ira Adams-Chapman et al. J Perinatol. 2021 Aug.

Abstract

Objective: This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial.

Study design: Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed.

Results: Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40).

Conclusions: Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Disclosures

None of the authors report any commercial, proprietary, or financial interest in any of the products described in this article. NICHD is the sponsor of the study and holds the investigational new drug (IND) application.

Abbott Nutrition Division, Abbott Laboratories, Columbus, OH, provided the inositol product. They had no role in the: design of the trial; the analyses, interpretation, or writing of the manuscript; or the decision to submit the manuscript for publication. They provided on-site monitoring to assist in quality assurance of the data collection.

Figures

Figure 1:
Figure 1:
Consort Diagram
Figure 2:
Figure 2:
Kaplan Meier Curve through 24 month follow-up

References

    1. Hasan SH, Nishigaki I, Tsutsui Y, Yagi K. Studies on myoinositol. IX. Morphological examinaiton of the effect of massive doses of myoinositol on the liver and kidney of rat. Journal of Nutritional Science and Vitaminology. 1974;20(1):55–58. - PubMed
    1. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol Supplementation in Premature Infants with Respiratory Distress Syndrome. New England Journal of Medicine. 1992;326(19):1233–1239. - PubMed
    1. Hallman M, Järvenpää AL, Pohjavuori M. Respiratory distress syndrome and inositol supplementation in preterm infants. Archives of Disease in Childhood. 1986;61(11):1076–1083. - PMC - PubMed
    1. Howlett A, Ohlsson A, Plakkal N. Inositol in preterm infants at risk for or having respiratory distress syndrome. Cochrane Database Syst Rev. 2015(2):CD000366. - PubMed
    1. Phelps DL, Watterberg KL, Nolen TL, Cole CA, Cotten CM, Oh W, et al. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks’ Gestational Age: A Randomized Clinical Trial. JAMA. 2018;320(16):1649–1658. - PMC - PubMed

Publication types

Grants and funding